Clinical trials · Massachusetts
Cardiomyopathies clinical trials in Massachusetts
We’re tracking 34 recruiting cardiomyopathies studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT07771465RecruitingPhase 3
Long-term safety of danicamtiv for genetic dilated cardiomyopathy
This study checks the long-term safety and effectiveness of the drug danicamtiv in people with a genetic form of dilated cardiomyopathy, a condition where the heart muscle becomes weak and enlarged. If you've already completed the earlier DAN-301 study, this trial continues to monitor you while you keep taking the medication.
Boston, MassachusettsAges 18 years+ - NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
Boston, MassachusettsAges 14–65 - NCT07606274RecruitingPhase 1/Phase 2
Study of NVC-001 for heart muscle disease caused by LMNA gene change
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Boston, MassachusettsAges 18 years+ - NCT07218887RecruitingPhase 1/Phase 2
Gene therapy for BAG3-related heart failure
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
Boston, MassachusettsAges 18–70 - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Boston, MassachusettsAges 18 years+ - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Boston, MassachusettsAges 18–85 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
Boston, MassachusettsAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Boston, MassachusettsAges 18 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Boston, MassachusettsAges 18–75 - NCT06138873Recruiting
Study of scar-guided ablation for ventricular tachycardia
This trial is testing a new approach to treating a fast, dangerous heart rhythm (ventricular tachycardia) that comes from scar tissue in people with ischemic cardiomyopathy. The goal is to use a special mapping technique to guide the ablation (a procedure that destroys the tiny area causing the problem) to stop the arrhythmia.
Boston, MassachusettsAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Boston, MassachusettsAges 18–90 - NCT02641145Recruiting
PET/MRI scans in light-chain amyloid heart disease
This study uses special PET and heart MRI scans to better understand light-chain amyloidosis affecting the heart. The scans may help researchers see how the disease behaves in different patient groups and treatment states.
Boston, MassachusettsAges 18–99 - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Boston, MassachusettsAges 18 years+ - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Boston, MassachusettsAges 18 years+ - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Boston, MassachusettsAges 18 years+ - NCT07690436Recruiting
Eye imaging for detecting a type of heart disease
This study uses retinal imaging (pictures of the back of the eye) and OCT scans to look for signs of a specific heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It may help doctors find this condition with an eye exam instead of more invasive tests.
Boston, MassachusettsAges 18 years+ - NCT06551129Recruiting
Camzyos treatment in real life: patient experiences
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
Boston, MassachusettsAges 18 years+ - NCT07560306RecruitingPhase 3
New Heart Scan to Detect Blood Clots in Amyloid Heart Disease
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
Boston, MassachusettsAges 18 years+ - NCT06228924RecruitingPhase 1
Gene therapy for ARVC with PKP2 mutation
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
Boston, MassachusettsAges 18–65 - NCT07358078Recruiting
Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Boston, MassachusettsAges 18 years+ - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Boston, MassachusettsAges 18 years+ - NCT07054073Recruiting
HCMR Re-Imaging: MRI follow-up for HCM patients
This study uses MRI scans to re-examine people with hypertrophic cardiomyopathy (a thickening of the heart muscle) who were part of the original HCMR study. It compares different types of HCM to learn more over time.
Medford, MassachusettsAges 18–65
Cardiomyopathies trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- Brigham and Women's Hospital · 13 studies
- Massachusetts General Hospital · 5 studies
- Clinical Trial Site · 3 studies
- Boston University School of Medicine · 2 studies
- Research Site · 2 studies
- Tufts Medical Center · 2 studies
- Analysis Group Inc.
- Boston Medical Center
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in Massachusetts?
- Yes. We're currently tracking 34 recruiting cardiomyopathies studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.